Smith+Nephew to feature leading rotator cuff repair portfolio including new Tendon Seam(TM) Repair System and REGENETEN? Bioinductive Implant at AAOS 2026
MWN-AI** Summary
Smith+Nephew (LSE:SN, NYSE:SNN) is poised to showcase its advanced rotator cuff repair (RCR) portfolio at the 2026 American Academy of Orthopaedic Surgeons (AAOS) Annual Meeting in New Orleans. With around 500,000 RCR procedures performed annually in the U.S. and significant failure rates of 20-40% with traditional methods, Smith+Nephew aims to address these challenges with innovative solutions such as the Tendon Seam™ Repair System and the REGENETEN® Bioinductive Implant.
The Tendon Seam Repair System introduces a pioneering biomechanical repair technique. Featuring a unique suture configuration, patented microanchors, and a streamlined implantation instrument, this system is designed to enhance surgical efficiency while providing robust and stable repairs. It received 510(k) clearance in 2023 and is indicated for the reattachment of various soft tissues, including tendons and ligaments. By reducing re-tear rates, Tendon Seam aims to significantly improve patient outcomes compared to existing treatment options.
Complementing the Tendon Seam system, the REGENETEN Bioinductive Implant has revolutionized RCR through its collagen-based design, promoting new tissue formation that augments the body's natural healing process. Since its launch in 2014, over 250,000 procedures have utilized the implant, underscoring its efficacy, which is backed by randomized clinical trial data illustrating improved outcomes versus traditional repairs.
This year marks the first AAOS meeting since the publication of a revised Clinical Practice Guideline endorsing bioinductive implants, which emphasizes their role in lowering re-tear rates and improving patient-reported outcomes. Attendees can visit Smith+Nephew's booth (#839) to explore these groundbreaking advancements in joint repair solutions for Sports Medicine.
MWN-AI** Analysis
As a financial analyst, it is essential to assess Smith+Nephew (LSE: SN, NYSE: SNN) in the context of its leading position in the rotator cuff repair (RCR) market as it showcases innovative products like the Tendon Seam™ Repair System and REGENETEN® Bioinductive Implant at the 2026 AAOS Annual Meeting. With a staggering 500,000 procedures performed annually in the U.S., coupled with 20-40% structural failure rates in traditional approaches, there exists significant market potential for Smith+Nephew’s advanced technologies, which focus on enhancing surgical outcomes and reducing re-tear rates.
The Tendon Seam, cleared by the FDA in 2023, represents a transformative biomechanical approach with its patented design promoting a stable repair while optimizing surgical ease. This can potentially catalyze market penetration, appealing not only to surgeons but also to patients seeking effective solutions. Meanwhile, the REGENETEN Bioinductive Implant's success, evidenced by over 250,000 procedures since 2014, highlights its role as a market leader that leverages biological augmentation for improved healing, further validated by the recent guidelines from AAOS advocating bioinductive solutions.
In terms of market positioning, Smith+Nephew’s dual approach—providing both biomechanical repair and biological enhancement—Sets it apart in an evolving landscape that increasingly favors innovation. The strong recommendation from AAOS regarding bioinductive implants signifies a shift in surgical practice that Smith+Nephew is well-positioned to capitalize on, potentially leading to increased adoption and market share.
From a financial standpoint, investing in Smith+Nephew could be advantageous. The convergence of innovative products and a favorable market environment suggests a strong growth trajectory. Analysts should consider Smith+Nephew as a robust player in the orthopedic space with the capability to deliver sustained financial performance and value creation. For investors looking at exposure in the healthcare sector, Smith+Nephew stands out as a promising opportunity.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Uniting the most advanced technologies for biomechanical repair and biological augmentation
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces it will showcase its unrivalled portfolio for rotator cuff repair (RCR) during the 2026 American Academy of Orthopaedic Surgeons (AAOS) Annual Meeting in New Orleans this week. RCR is a growing market segment with approximately 500,000 procedures performed annually in the US,1 yet still experiencing 20–40%2 structural failure rates using traditional surgical techniques.
Tendon Seam offers a new and unique biomechanical repair technique alongside market-leading biological augmentation of the REGENETEN Bioinductive Implant, giving Smith+Nephew a differentiated and disruptive RCR portfolio. These technologies aim to drive better outcomes – through immediate biomechanical repair to improve early outcomes and biological augmentation supporting tendon integrity.
The newly acquired Tendon Seam is designed to reduce re?tear rates and improve patient outcomes versus the current standard of care. Its novel repair stitch configuration with multiple points of fixation, patented microanchors, continuous suture, individually locked stitches, and integrated implantation instrument are designed to deliver strong and stable repairs with a simplified surgical technique. The system received 510(k) clearance in 2023 and is indicated for reattachment of soft tissue to bone, including tendons, ligaments, and joint capsules.
With more than 250,000 procedures4 completed globally since its introduction in 2014, the REGENETEN Bioinductive Implant has had a transformative impact, offering a better solution for thousands of patients with rotator cuff injuries every year.5 The collagen-based implant supports the body’s natural healing response to facilitate the formation of new tissue to biologically augment repairs – demonstrated by Randomized Control Trial (RCT) data showing improved outcomes versus traditional repair.6-10
This year’s meeting will be the first since AAOS published its revised Clinical Practice Guideline (CPG) that supports the use of bioinductive implants for rotator cuff repair. The American Academy of Orthopaedic Surgeons (AAOS) CPG on the ‘Management of Rotator Cuff Injuries’ highlights the value of bioinductive implants in rotator cuff repair based on independent analysis of studies. Analyzing RCTs for bioinductive implants, AAOS have issued a Strong Recommendation that:
‘The use of bioinductive tendon implants to augment rotator cuff repair, or as an alternative to standard repair, can lead to lower re-tear rates and better patient reported outcomes.’
To learn more about Smith+Nephew’s joint repair solutions for Sports Medicine and our leading rotator cuff repair portfolio, please visit our booth (#839) at AAOS in New Orleans, March 2-6, 2026 or visit www.smith-nephew.com.
- ends –
Media Enquiries
Dave Snyder +1 (978) 749-1440
Smith+Nephew david.snyder@smith-nephew.com
References
- SmartTRAK, 2025, Shoulder Soft Tissue Fixation, 2025 BioMedGPS — SmartTRAK.
- Hein J, et al. Arthroscopy. 2015;31(11):2274-2281.
- Data on File at Integrity Orthopaedics.
- Smith+Nephew. Internal Data.
- FDA. 510(k) Premarket Notification: K242631 [Accessed May 2025]
- Bokor DJ, Sonnabend D, Deady L, et al. Evidence of healing of partial-thickness rotator cuff tears following arthroscopic augmentation with a collagen implant: a 2-year MRI follow-up. Muscles,Ligaments Tendons J 2016;6(1):16-25.
- Bokor DJ, Sonnabend DH, Deady L, et al. Healing of partial-thickness rotator cuff tears following arthroscopic augmentation with a highly porous collagen implant: a 5-year clinical and MRI follow-up. Muscles, Ligaments Tendons J 2019;9(3):338-347.
- Ruiz Iban MA, et al. Arthroscopy. Apr 08 2025 [ePub Ahead of Print].
- Ruiz Iban MA, et al. Arthroscopy. 2024;40(6):P1760-1773.American Academy of Orthopedic Surgeons (AAOS). Rotator Cuff Repair Clinical Practice Guideline. Available at: https://www.aaos.org/quality/quality-programs/rotator-cuff/. [Accessed August 2025].
- Camacho Chacón JA, Roda Rojo V, Martin Martinez A, et al. An isolated bioinductive repair vs sutured repair for full-thickness rotator cuff tears: 2-year results of a double blinded, randomized controlled trial. J Shoulder Elbow Surg. 2024;33(9):1894-1904. doi: 10.1016/j.jse.2024.03.043
About Smith+Nephew
Smith+Nephew is a portfolio medical technology business focused on the repair, regeneration and replacement of soft and hard tissue. We exist to restore people’s bodies and their self-belief by using technology to take the limits off living. We call this purpose ‘Life Unlimited’. Our 17,000 employees deliver this mission every day, making a difference to patients’ lives through the excellence of our product portfolio, and the invention and application of new technologies across our three global business units of Orthopaedics, Sports Medicine & ENT and Advanced Wound Management.
Founded in Hull, UK, in 1856, we now operate in around 100 countries, and generated annual sales of $6.2 billion in 2025. Smith+Nephew is a constituent of the FTSE100 (LSE:SN, NYSE:SNN). The terms ‘Group’ and ‘Smith+Nephew’ are used to refer to Smith & Nephew plc and its consolidated subsidiaries, unless the context requires otherwise.
For more information about Smith+Nephew, please visit www.smith-nephew.com and follow us on X, LinkedIn, Instagram or Facebook.
Forward-looking Statements
This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading profit margins, market trends and our product pipeline are forward-looking statements. Phrases such as "aim", "plan", "intend", "anticipate", "well-placed", "believe", "estimate", "expect", "target", "consider" and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith+Nephew, these factors include: conflicts in Europe and the Middle East, economic and financial conditions in the markets we serve, especially those affecting healthcare providers, payers and customers; price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls or other problems with quality management systems or failure to comply with related regulations; litigation relating to patent or other claims; legal and financial compliance risks and related investigative, remedial or enforcement actions; disruption to our supply chain or operations or those of our suppliers; competition for qualified personnel; strategic actions, including acquisitions and disposals, our success in performing due diligence, valuing and integrating acquired businesses; disruption that may result from transactions or other changes we make in our business plans or organisation to adapt to market developments; relationships with healthcare professionals; reliance on information technology and cybersecurity; disruptions due to natural disasters, weather and climate change related events; changes in customer and other stakeholder sustainability expectations; changes in taxation regulations; effects of foreign exchange volatility; and numerous other matters that affect us or our markets, including those of a political, economic, business, competitive or reputational nature. Please refer to the documents that Smith+Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith+Nephew's most recent annual report on Form 20-F, which is available on the SEC’s website at www. sec.gov, for a discussion of certain of these factors. Any forward-looking statement is based on information available to Smith+Nephew as of the date of the statement. All written or oral forward-looking statements attributable to Smith+Nephew are qualified by this caution. Smith+Nephew does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Smith+Nephew's expectations.
? Trademark of Smith+Nephew. Certain marks registered in US Patent and Trademark Office.
FAQ**
How does the introduction of the Tendon Seam technology by Smith & Nephew Plc Ord SNNUF aim to reduce the structural failure rates associated with traditional rotator cuff repair techniques?
What specific data from clinical trials supports the effectiveness of the REGENETEN Bioinductive Implant in enhancing patient outcomes compared to traditional rotator cuff repair methods, particularly for Smith & Nephew Plc Ord SNNUF?
In light of the AAOS's strong recommendation for bioinductive implants, how does Smith & Nephew Plc Ord SNNUF plan to leverage this endorsement to expand its market share in the growing rotator cuff repair segment?
What are the anticipated financial impacts for Smith & Nephew Plc Ord SNNUF as it showcases its advanced rotator cuff repair technologies during the 2026 AAOS Annual Meeting and positions itself in a competitive landscape?
**MWN-AI FAQ is based on asking OpenAI questions about Smith & Nephew SNATS Inc. (NYSE: SNN).
NASDAQ: SNN
SNN Trading
-1.12% G/L:
$34.38 Last:
347,571 Volume:
$34.77 Open:
